Cost-Effectiveness Analysis of a Mobile-Based Intervention for Patients with Type 2 Diabetes Mellitus

Jing Li, Li Sun, Yabing Hou, Liming Chen, Jing Li, Li Sun, Yabing Hou, Liming Chen

Abstract

Objective: The aim of this study was to evaluate the cost effectiveness of a mobile-based intervention for patients with type 2 diabetes mellitus (T2DM) and compare it with the usual management mode.

Method: A total of 215 patients with T2DM in a tertiary-care hospital specific to diabetes were selected as the study population. This study was conducted from January 1, 2019 to January 1, 2020. Of the 215 patients, 130 were randomly assigned to the mHealth group and 85 were assigned to the usual care group. IBM SPSS 25.0 software was used for descriptive statistics, t tests, chi-square tests, and correlation analyses. Haemoglobin A1c (HbA1c) was the effectiveness parameter adopted. Cost-effectiveness analyses were performed, and incremental cost-effectiveness ratios (ICERs) were calculated.

Results: Of the 215 patients with T2DM, the proportion of male patients was 66.0%. The mean age of the patients was 47.2 (SD 9.95). Differences in baseline information were not statistically significant between the two groups (P > 0.05). At the 3-, 6-, and 12-month follow-ups, the mHealth group reported higher control rates of HbA1c than the usual care group, 67.9% versus 46.2% (P < 0.001), 72.4% versus 45.4% (P < 0.001), and 74.6% versus 47.1% (P < 0.001), respectively. The value of HbA1c was positively related to total patient cost, material fee, Western medicine fee, and hospitalization expenses (P < 0.05), with correlation coefficients of 0.202, 0.200, 0.172, and 0.183, respectively. The costs of the mHealth group and usual care group were CNY¥ 1169.76 and CNY¥ 1775.44 per patient/year, respectively. The incremental cost of the mHealth intervention was CNY¥ -605.68 per patient/year. The ICER was CNY¥ -22.02 per patient/year.

Conclusion: Compared with the usual care mode, the mHealth management model for patients with T2DM improved the control rate of HbA1c, and the mHealth management mode had better cost effectiveness.

Conflict of interest statement

The authors declare no conflicts of interest.

Copyright © 2021 Jing Li et al.

Figures

Figure 1
Figure 1
The linear associations between HbA1c and total patient cost.

References

    1. World Health Organization. Global Report on Diabetes. Geneva, Switzerland: World Health Organization; 2013. .
    1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. doi: 10.2337/diacare.27.5.1047.
    1. Hou Q., Li H., Li S., et al. Global burden of diabetes mellitus. Chinese Journal of Diabetes. 2016;24(1):92–96.
    1. Hu J., Rao K., Qian J., et al. Economic burden of chronic diseases in China. Prevention and Control of Chronic Diseases in China. 2007;15(3):189–193.
    1. Xu Z., Hu C., Liu Y., et al. Analysis of hospitalization expenses of diabetes mellitus from 1995-1999. Chinese Journal of Diabetes. 2001;9(5):298–302.
    1. Editorial office. The social burden of diabetes is heavy - the total medical cost of urban patients exceeds 20 billion every year. Health Soft Science. 2003;1:23–26.
    1. Li J., Sun L. A mobile-based intervention for glycemic control in patients with type 2 diabetes: retrospective, propensity score-matched cohort study. JMIR mHealth and uHealth. 2020;8(3) doi: 10.2196/15390.e15390
    1. Chinese Diabetes Society. Guidelines for the prevention and control of type 2 diabetes in China (2017 Edition) Chinese Journal of Practical Internal Medicine. 2018;38(4):292–344.
    1. Li R., Zhang P., Barker L. E., Chowdhury F. M., Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33(8):1872–1894. doi: 10.2337/dc10-0843.
    1. Herman W. H., Dasbach E. J., Songer T. J., Eastman R. C. The cost-effectiveness of intensive therapy for diabetes mellitus. Endocrinology and Metabolism Clinics of North America. 1997;26(3):679–695. doi: 10.1016/s0889-8529(05)70274-7.
    1. Sidorov J., Shull R., Tomcavage J., Girolami S., Lawton N., Harris R. Does Diabetes Disease Management Save Money and Improve Outcomes?: a report of simultaneous short-term savings and quality improvement associated with a health maintenance organization-sponsored disease management program among patients fulfilling health employer data and information set criteria. Diabetes Care. 2002;25(4):684–689. doi: 10.2337/diacare.25.4.684.
    1. Johansson P., Ostenson C. G., Hilding A. M., Andersson C., Rehnberg C., Tillgren P. A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden. International Journal of Technology Assessment in Health Care. 2009;25(3):350–358. doi: 10.1017/S0266462309990079.
    1. Wier M., Lakerveld J., Bot S., et al. Economic evaluation of a lifestyle intervention in primary care to prevent type 2 diabetes mellitus and cardiovascular diseases: a randomized controlled trial. BMC Family Practice. 2013;14:14–26. doi: 10.1186/1471-2296-14-45.
    1. Sagarra R., Costa B., Solà-Morales J. J., Barrio F. Lifestyle interventions for diabetes mellitus type 2 prevention. Revista Clínica Española (English Edition) 2014;214(2):59–68. doi: 10.1016/j.rceng.2013.11.003.
    1. Gillespie P., O’Shea E., O’Hara E., Dinneen S. F. Cost effectiveness of group follow-up after structured education for type 1 diabetes: a cluster randomised controlled trial. Trials. 2014;15(1):227–239. doi: 10.1186/1745-6215-15-227.
    1. Loveman E., Cave C., Green C., et al. The clinical and cost-effectiveness of patient education models for diabetes: a systematic review and economic evaluation. Health Technology Assessment. 2003;22(7):172–190.
    1. Carls G. S., Gibson T. B., Driver V. R., et al. The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers. Journal of the American Podiatric Medical Association. 2011;101(2):93–115. doi: 10.7547/1010093.
    1. Wu J., He X., Liu Y. The Cost effectiveness analysis of insulin aspart 30 and insulin glargine in patients with type 2 diabetes mellitus in China. Chinese Journal of Pharmacy. 2016;51(3):242–247.
    1. Brownson C. A., Hoerger T. J., Fisher E. B., Kilpatrick K. E. Cost-effectiveness of diabetes self-management programs in community primary care settings. The Diabetes Educator. 2009;35(5):761–769. doi: 10.1177/0145721709340931.
    1. Gillett M., Dallosso H., Dixon S., et al. Delivering the diabetes education and self management for ongoing and newly diagnosis (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. British Medical Association. 2010;341 doi: 10.1136/bmj.c4093.C4093
    1. Volmink H. C., Bertram M. Y., Jina R., Wade A. N., Hofman K. J. Applying a private sector capitation model to the management of type 2 diabetes in the South African public sector: a cost-effectiveness analysis. BMC Health Services Research. 2014;14(1):444–453. doi: 10.1186/1472-6963-14-444.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe